Second Phase III Ovarian Cancer Trial Finds Avastin-Chemotherapy Combo Boosts PFS
Roche claims latest study data in newly diagnosed women confirms findings from previous trial.
A second Phase III trial has shown that using Avastin® to treat ovarian cancer significantly increases progression-free survival (PFS) in women with newly diagnosed disease, Roche reports. Initial data from the ICON7 study has shown that in comparison with chemotherapy alone, treating patients using chemotherapy plus Avastin followed by continued Avastin monotherapy boosted PFS. Roche says data from the Phase III study will be presented at a forthcoming medical meeting.
The ICON7 trial is evaluating Avastin in combination with carboplatin and paclitaxel in 1,528 women with newly diagnosed ovarian cancer who have undergone surgery. Roche says the results uphold those from another Phase III study, GOG0218, in women with previously untreated advanced ovarian cancer.
The Phase III program for Avastin in ovarian cancer includes a number of trials combining the anti-angiogenic therapy with other agents for the treatment of various stages of the disease.